Manufacturing & Quality

Three sites, one quality system.

Our manufacturing spans India and Oman. Puducherry is in production, Sanand is being built for scale, and Oman will formulate and fill for global markets. Together they cover the full chain, from drug substance to finished cartridge.

Overview

Our sites.

Drug substance and fill-finish

Puducherry, India

WHO-GMP certified

Commercial drug substance and fill-finish

Sanand, Gujarat, India

Under construction; commercial 2028 (planned)

Formulation and fill-finish

Khazaen Economic City, Oman

Under development; commercial 2029 (planned)

Puducherry

Our operating site, being upgraded to global standards.

Our Puducherry plant stands on a 20,500 square-metre site. It makes drug substance, finished product and clinical supplies for all three insulin analogues, as well as our recombinant enzymes.

The plant is WHO-GMP certified and is being upgraded to EU-GMP and PIC/S standards, ahead of our European filing.

20,500 m² siteWHO-GMP certifiedBeing upgraded to EU-GMP and PIC/SDrug substance · finished product · clinical supplies

Sanand

Built for scale.

Our Sanand facility in Gujarat, on a ~40,000 square-metre site, will make drug substance and finished product (fill-finish) at commercial scale. It is designed to the Standard of the European Medicine Agency, WHO and to ICH guidelines.

~40,000 m² siteDrug substance · fill-finishCommercial 2028 (planned)EMA · WHO · ICH

Oman

Fill-finish for global markets.

Our subsidiary, BioGenomics International SPC, is building a formulation and fill-finish facility on a 23,000 square-metre site at Khazaen Economic City, Oman.

The facility targets compliance with the Ministry of Health of Oman (MOH Oman), the European Medicines Agency (EMA) and the Saudi Food and Drug Authority (SFDA). Commercial operation is planned for 2029.

23,000 m² siteCommercial 2029 (planned)MOH Oman · EMA · SFDA

Quality system

Every cartridge must be one a doctor can trust.

One quality system governs every site, every batch and every release. It covers:

Supply security

Supply you can rely on.

Vendor management

At least three qualified suppliers for every critical material.

For every critical raw material and component, we qualify at least three suppliers. Each is audited, approved and bound by a quality agreement.

If one supplier fails, production continues. A person on insulin cannot wait for a shortage to resolve.

Supply chain & continuity

A managed chain, from India to the world.

Drug substance and finished product are made in India: at Puducherry today and, from 2028, also at Sanand. From 2029, Oman adds formulation and fill-finish. When both new sites are complete, every product will have at least two sources of drug substance and of fill-finish.

01

Today

Drug substance and fill-finish at Puducherry.

02

2028

Sanand adds drug substance and fill-finish.

03

2029

Oman adds fill-finish.

04

Then

At least two sources of drug substance and of fill-finish for every product.

Validated cold chain from plant to partner.

Safety stocks of critical materials and finished product.

Forecast-based planning shared with each partner.

Business continuity plans for each site.